News

Addition of 177Lu-PSMA-617 to Enzalutamide Improves PSA Outcomes Among Patients With Metastatic Castration-Resistant Prostate Cancer

11/06/2023

Allison Casey ;

A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.

A phase 2 study found that...

11/06/2023

Oncology

News

Biweekly Cabazitaxel Regimen Reduces Occurrence of Neutropenia Among Older Patients With Metastatic Castration-Resistant Prostate Cancer

11/06/2023

Allison Casey ;

According to results from a phase 3 clinical trial, biweekly cabazitaxel reduced the rate of neutropenia among older patients with metastatic castration-resistant prostate cancer.

According to results from a...

11/06/2023

Oncology

News

Stereotactic Body Radiation Therapy May Benefit Patients With Oligometastatic Castration-Resistant Prostate Cancer

10/13/2023

Allison Casey ;

In the phase 2 ARTO trial, targeting oligometastatic sites of disease with SBRT and standard-of-care abiraterone acetate was found to enhance response rates and prolong time to radiographic progression among patients with castration-resistant...

In the phase 2 ARTO trial,...

10/13/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey ;

In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...

In the second interim analysis...

09/14/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey ;

In the second interim analysis...

09/14/2023

Oncology

News

FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for Castration-Resistant Prostate Cancer

08/15/2023

Stephanie Holland ;

On August 11, 2023, the FDA granted approval to niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer, based on results from the MAGNITUDE study.

On August 11, 2023, the FDA...

08/15/2023

Oncology

News

Darolutamide Improved Survival Outcomes for Patients With Castration-Resistant Prostate Cancer and Substantial Comorbidity Burden

08/10/2023

Allison Casey ;

In the phase 3 ARAMIS trial, patients with castration-resistant prostate cancer and high numbers of comorbidities experienced a similar benefit from darolutamide as those in the general trial population.

In the phase 3 ARAMIS trial,...

08/10/2023

Oncology

News

Pembrolizumab-Olaparib Combination Did Not Improve Survival Outcomes Among Patients With Metastatic Castration-Resistant Prostate Cancer

07/20/2023

Allison Casey ;

In a phase 3 study, pembrolizumab plus olaparib did not improve the progression-free survival or overall survival of patients with metastatic castration-resistant prostate cancer, when compared with next-generation hormonal agents.

In a phase 3 study,...

07/20/2023

Oncology

News

Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

06/21/2023

On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

On June 20, 2023, the US FDA...

06/21/2023

Oncology

News

Olaparib Plus Abiraterone and Prednisone Granted FDA Approval for BRCA-Mutated Prostate Cancer

06/02/2023

Allison Casey ;

On May 31, 2023, the FDA approved olaparib plus abiraterone and prednisone for patients with metastatic castration-resistant prostate cancer with BRCA mutations.

On May 31, 2023, the FDA...

06/02/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology